Abstract 110P
Background
D3 lymph node dissection or complete mesocolic excision (CME) with central vascular ligation (CVL) is becoming standard procedure in advanced right colon cancer with increasing evidences of its oncologic benefit. However, clear indication has not been declared and evidences to lighten the undetermined area is not satisfactory yet. There is still a controversy whether D3 lymph node dissection is necessary in clinical stage I right colon cancer.
Methods
We retrospectively analyzed clinical stage I right colon cancer patients who underwent radical surgery in three Korea university hospitals from January 2015 to June 2018. We compared surgical complications and short-term oncologic outcome between D2 and D3 lymph node dissections in clinical stage I right colon cancer patients.
Results
602 patients had radical surgery for right colon cancer in the study period and the number of clinical stage I patients was 125 (20.8%). Among 125 patients, D2 lymph node dissection was done in 86 patients (68.8%) and 39 patients underwent D3 lymph node dissection. There was no statistically significant differences in clinicopathologic variables and surgical outcomes between two groups. Up-stagings were found in 15 patients (38.5%) in D3 group and 18 patients (20.9%) in D2 group. There were four recurrences in D2 lymph node dissection group but no recurrences in D3 group. Log-rank test was performed and there was no statistically significant difference in recurrence-free survival rate between two groups (p = 0.2).
Conclusions
There was no significant difference in recurrence-free survival rate between D2 and D3 lymph node dissection in clinical stage I right colon cancer patients. But recurrences had occurred in D2 group. Efforts to make clinical staging more accurate is required and more studies with better quality are needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
YO20 - Can "Superman" have Chronic Myelomonocytic Leukemia?
Presenter: Alexander Luchinin
Session: Poster display session
Resources:
Abstract
YO21 - Sanctuary Site Central Nervous System Relapse-Refractory DLBCL Responding to Nivolumab and Lenalidomide.
Presenter: Irappa Madabhavi
Session: Poster display session
Resources:
Abstract
YO22 - External Auditory Canal Mass: A Case Series of Squamous Cell Carcinoma
Presenter: Mel Valerie Cruz-Ordinario
Session: Poster display session
Resources:
Abstract
YO23 - Soft tissue Giant cell tumor presented as Nasopharyngeal mass: A case report
Presenter: Emmelyn Buenacosa-Nepucpan
Session: Poster display session
Resources:
Abstract
YO25 - Hyperprogression after pembrolizumab in recurrent oropharyngeal cancer and the use of nab-paclitaxel as salvage treatment- A case report.
Presenter: Izzati Rosli
Session: Poster display session
Resources:
Abstract
YO26 - Exacerbation of radiation necrosis around the radiotherapy-pretreated brain metastases site after immune checkpoint inhibitors.
Presenter: Minako Nishio
Session: Poster display session
Resources:
Abstract
YO27 - Comparative Study Of 20Gray/5Fraction And 30Gray/10 Fraction Whole Brain Radiation In Brain Metastasis
Presenter: Pradip Bhandari
Session: Poster display session
Resources:
Abstract
YO28P - The response to anaplastic lymphoma kinase (ALK) inhibitor in metastatic anaplastic thyroid carcinoma (ATC)
Presenter: Nur Faizah Ab Muin
Session: Poster display session
Resources:
Abstract
YO29 - Acute kidney injury secondary to bilateral renal artery tumor thrombosis in a case of posterior mediastinal undifferentiated sarcoma: case report
Presenter: Ritsu Ibusuki
Session: Poster display session
Resources:
Abstract
YO30 - Follicular dendritic cell sarcoma of the tonsil- a multimodality approach
Presenter: Rich Ericson King
Session: Poster display session
Resources:
Abstract